Lola A. Fashoyin-Aje, MD, MPH, U.S. Food and Drug Administration, discusses the importance of improving diversity and inclusion in the demographics of clinical trial enrollment and highlights efforts made by the FDA in achieving this as well as the key challenges associated. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

свернуть